Storage Symptoms, a Borderline Residual, and Which Drug Class Avoids the Question
A man's urge incontinence isn't controlled on an alpha-blocker alone, and his post-void residual sits in the upper reach of what the trial evidence for adding an anticholinergic actually studied. The debate isn't really about that edge — it's about whether a different drug class makes the edge irrelevant.
W.H., 72, moved into an active-adult community two years ago and has settled into a regular Tuesday-night bridge group he says is "the best thing about retirement" — except that lately he's been slipping out mid-game to find a bathroom, sometimes not making it in time. He has BPH and has been on tamsulosin for two years with reasonable relief of his stream and hesitancy, but the urgency and frequency have gotten worse over the last six months, and he's had two episodes of urge incontinence he's embarrassed to describe in detail. He is otherwise in good health — well-controlled hypertension on amlodipine, no diabetes, no prior surgeries — and until this symptom shift, his BPH had been the quietest part of his medical history, not the loudest.
His post-void residual on today's bladder scan is 160mL. TIMES — the randomized trial of adding tolterodine to an alpha-blocker — enrolled men with a residual under 200mL and a peak flow above 5mL/s, so he is inside the population it studied rather than outside it; but 160mL sits in the top fifth of that enrolled window, and TIMES ran only twelve weeks. His flow rate is preserved, and he has no history of retention — the obstructive side of his BPH looks stable even as the storage side has clearly worsened, which is exactly the kind of split picture that makes a residual in the upper reach of a short trial's enrolled range worth taking seriously rather than rounding down. He takes no other regular medications besides tamsulosin, amlodipine, and a daily multivitamin, and he has mentioned, unprompted, that he'd rather not add "one of those bladder pills" if there's another way to fix this, having read that they can affect memory in people his age.
Adding a second drug without adding a second risk
Tamsulosin alone isn't controlling his storage symptoms, and TIMES showed real benefit from adding tolterodine to an alpha-blocker in men with this presentation, without a significant rise in retention in the population it studied. That's the combination with dedicated trial support for exactly his problem.
I'd look more closely at where his numbers actually sit. TIMES capped enrollment at a residual under 200mL, so at 160mL he is inside it — but he's in the top fifth of that range, and the trial ran twelve weeks. Its reassurance about retention is thinnest exactly where he sits and over a window shorter than the therapy he'd actually be on. That's not a rejection of the drug class — it's a concern about how much that safety margin covers a patient at the upper end of it.
Fair — "no significant rise in retention" describes a twelve-week result across the whole enrolled range, and I'd concede that isn't the same as a result specific to men in its upper reach.
There's a way to make that boundary question irrelevant. Mirabegron treats the same storage symptoms through beta-3 receptor agonism, with no antimuscarinic retention signal to worry about at any residual volume — and separately, he's 72 and already told us directly he's worried about cognitive effects from "bladder pills." That's not a vague concern; anticholinergic burden has real, independent relevance to cognition in older adults regardless of how the retention question resolves. One drug switch answers both problems he actually has.
Agreed: add mirabegron 25mg daily with baseline and follow-up blood pressure checks, continue tamsulosin, and repeat the post-void residual in four to six weeks.
Not agreed: whether to increase the tamsulosin dose at the same visit or hold it steady to isolate mirabegron's own effect on the follow-up residual reading — the urologist wants a clean readout, the geriatrician doesn't want his storage symptoms undertreated in the meantime for the sake of a tidier measurement.